

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Evaluation of the effect of reduced dose of long-acting gonadotropin releasing hormone (GnRH) agonist versus short acting GnRH agonist on pregnancy outcome in patients undergoing intracytoplasmic sperm injection outcome- clinical trial

#### Protocol summary

##### Study aim

The aim of present study is to evaluate the effect of reduced dose of long-acting gonadotropin releasing hormone (GnRH) agonist versus short acting GnRH agonist on pregnancy outcome in patients undergoing intracytoplasmic sperm injection outcome.

##### Design

Phase III, with a parallel group, double blinded, randomized clinical trial with 400 participants in two groups of long (n=200) and short-acting gonadotropin releasing hormone (GnRH) agonist (n=200)

##### Settings and conduct

The aim of present study is to evaluate the effect of reduced dose of long-acting gonadotropin releasing hormone (GnRH) agonist versus short acting GnRH agonist on pregnancy outcome in patients undergoing intracytoplasmic sperm injection outcome at Mehr medical institute. Block randomization will be done with a 4:4 allocation ratio. The physicians and patients will be blinded to group assignment.

##### Participants/Inclusion and exclusion criteria

Normal responders to ovarian induction Inclusion criteria: Age  $\leq$  40 years, Basal FSH level  $<$ 8, Less than one failed ICSI cycle, Non PCOS patients, No azoospermia, No moderate to severe endometriosis Exclusion criteria: No response to ovulation induction, Difficult embryo transfer, Bloody embryo transfer

##### Intervention groups

First group: long-acting gonadotropin releasing hormone (GnRH) agonist Second group: short-acting gonadotropin releasing hormone (GnRH) agonist

##### Main outcome variables

Biochemical and clinical pregnancy rate will be considered as main endpoint.

#### General information

##### Reason for update

Completion of the project

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190609043845N1**  
Registration date: **2019-06-20, 1398/03/30**  
Registration timing: **prospective**

Last update: **2023-06-20, 1402/03/30**

Update count: **2**

##### Registration date

2019-06-20, 1398/03/30

##### Registrant information

##### Name

Roya Kabodmehri

##### Name of organization / entity

Guilan university of medical sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 13 3336 9224

##### Email address

drkabodmehri@gums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-07-29, 1398/05/07

##### Expected recruitment end date

2020-01-27, 1398/11/07

##### Actual recruitment start date

2019-07-29, 1398/05/07

##### Actual recruitment end date

2020-02-17, 1398/11/28

**Trial completion date**

2020-07-28, 1399/05/07

**Scientific title**

Evaluation of the effect of reduced dose of long-acting gonadotropin releasing hormone (GnRH) agonist versus short acting GnRH agonist on pregnancy outcome in patients undergoing intracytoplasmic sperm injection outcome- clinical trial

**Public title**

Effect of reduced dose of long-acting GnRH agonist versus short acting GnRH agonist

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

Age ≤ 40 years Basal FSH level <8 Less than one failed ICSI cycle Non PCOS patients No azoospermia No moderate to severe endometriosis

**Exclusion criteria:**

No response to ovulation induction Difficult embryo transfer Bloody embryo transfer

**Age**

To 40 years old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider

**Sample size**

Target sample size: 400

Actual sample size reached: 400

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Block randomization will be done with a 4:4 allocation ratio.(<https://www.sealedenvelope.com>)

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Each patient will have an identification code (IC) which will be placed in sealed envelope by researcher. Also, medications will be placed in sealed containers with IC. The physicians and patients will be blinded to group assignment.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

1

**Ethics committee**

**Name of ethics committee**

Ethics committee of Guilan university of medical sciences

**Street address**

Research and technology of Guilan university of medical sciences, Shahid Siadati avenue, Namjoo street, Rasht, Iran

**City**

Rasht

**Province**

Guilan

**Postal code**

4144666949

**Approval date**

2019-05-25, 1398/03/04

**Ethics committee reference number**

IR.GUMS.REC.1398.094

**Health conditions studied**

1

**Description of health condition studied**

Infertility

**ICD-10 code**

N97

**ICD-10 code description**

Female infertility

**Primary outcomes**

1

**Description**

Biochemical pregnancy rate

**Timepoint**

Two month after intervention

**Method of measurement**

Positive βhCG test (Lab kit)

2

**Description**

Clinical pregnancy rate

**Timepoint**

Two month after intervention

**Method of measurement**

Assessment of gestational sac and fetal heartbeat at 7 weeks of gestation (Vaginal ultrasonography)

**Secondary outcomes**

1

**Description**

Gonadotropin dosage

### Timepoint

At the end of ovarian induction cycle

### Method of measurement

Total number of ampoule

## 2

### Description

Duration of ovarian induction

### Timepoint

At the end of ovarian induction cycle

### Method of measurement

Number of days

## Intervention groups

### 1

### Description

Intervention group: long-acting gonadotropin releasing hormone (GnRH) agonist: Decapeptyl (1.25mg, Ferring) will be injected on 21st day of menstruation before the start of ovarian induction cycle.

### Category

Treatment - Drugs

### 2

### Description

Intervention group: short-acting gonadotropin releasing hormone (GnRH) agonist: Cinnafact (Cinnagen) will be injected on 21st day of previous menstrual cycle at starting dose of 0.5 mg/daily and continued 0.25 mg/daily from 2st day of menstruation until the day of hCG administration.

### Category

Treatment - Drugs

## Recruitment centers

### 1

### Recruitment center

#### Name of recruitment center

Mehr Medical Institute

#### Full name of responsible person

Roya Kabodmehri

#### Street address

Reproductive Health Research Center, Alzahra Hospital, Namjoo Street, Rasht, Guilan, Iran

#### City

Rasht

#### Province

Guilan

#### Postal code

4144654839

#### Phone

+98 13 3336 9224

#### Email

royakabodmehri@yahoo.com

## Sponsors / Funding sources

### 1

### Sponsor

#### Name of organization / entity

Guilan University of Medical Sciences

#### Full name of responsible person

Dr Shadman Nemati

#### Street address

Research and Technology at Guilan University of Medical Sciences, Shahid Siadati avenue, Namjoo street, Rasht, Guilan, Iran

#### City

Rasht

#### Province

Guilan

#### Postal code

4144666949

#### Phone

+98 13 3333 5821

#### Email

research@gums.ac.ir

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Guilan University of Medical Sciences

### Proportion provided by this source

50

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

### 2

### Sponsor

#### Name of organization / entity

Mehr Fertility Research Center

#### Full name of responsible person

Marzieh Mehrafza

#### Street address

Mehr Fertility Research Center, Mehr Medical Institute, Ershad St., Shahid Ansari Blvd., Rasht, Iran

#### City

Rasht

#### Province

Guilan

#### Postal code

417861311

#### Phone

+98 13 3376 4270

#### Email

marzieh.mehrafza@gmail.com

**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Mehr Fertility Research Center  
**Proportion provided by this source**  
50  
**Public or private sector**  
Private  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Industry

## Person responsible for general inquiries

**Contact**  
**Name of organization / entity**  
Guilan University of Medical Sciences  
**Full name of responsible person**  
Roya Kabodmehri  
**Position**  
Assistant Professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Reproductive Biology  
**Street address**  
Reproductive Health Research Center, Alzahra  
Hospital, Namjoo Street, Rasht, Guilan, Iran  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
4144654839  
**Phone**  
+98 13 3336 9224  
**Email**  
royakabodmehri@yahoo.com

## Person responsible for scientific inquiries

**Contact**  
**Name of organization / entity**  
Guilan University of Medical Sciences  
**Full name of responsible person**  
Roya Kabodmehri  
**Position**  
Assistant Professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Reproductive Biology  
**Street address**  
Reproductive Health Research Center, Alzahra

Hospital, Namjoo Street, Rasht  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
4144654839  
**Phone**  
+98 13 3336 9224  
**Fax**  
**Email**  
drkabodmehri@gums.ac.ir

## Person responsible for updating data

**Contact**  
**Name of organization / entity**  
Guilan University of Medical Sciences  
**Full name of responsible person**  
Roya Kabodmehri  
**Position**  
Assistant Professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Reproductive Biology  
**Street address**  
Reproductive Health Research Center, Alzahra  
Hospital, Namjoo Street, Rasht  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
4144654839  
**Phone**  
+98 13 3336 9224  
**Fax**  
**Email**  
drkabodmehri@gums.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**  
No - There is not a plan to make this available  
**Justification/reason for indecision/not sharing IPD**  
There is no further information  
**Study Protocol**  
Yes - There is a plan to make this available  
**Statistical Analysis Plan**  
Not applicable  
**Informed Consent Form**  
Undecided - It is not yet known if there will be a plan to make this available  
**Clinical Study Report**  
Yes - There is a plan to make this available  
**Analytic Code**  
Not applicable  
**Data Dictionary**  
Not applicable  
**Title and more details about the data/document**  
Study Protocol and Clinical Study Report

**When the data will become available and for how long**

Starting after publication

**To whom data/document is available**

people working in academic institutions

**Under which criteria data/document could be used**

Starting after publication

**From where data/document is obtainable**

Roya Kabodmehri

**What processes are involved for a request to access data/document**

Email

**Comments**